Corvus Pharmaceuticals, Inc. (CRVS) Misses Q4 EPS by 6c
Tweet
Share
E-mail
Get Alerts CRVS Hot Sheet
Join SI Premium – FREE
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) reported Q4 EPS of ($0.18), $0.06 worse than the analyst estimate of ($0.12).
For earnings history and earnings-related data on Corvus Pharmaceuticals, Inc. (CRVS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ADP Employment Change (Aug) 38K vs 47K Expected
- Eco Wave Power signs deal with AI engineering GmbH on digital twin platform
- Contango Silver & Gold reports high-grade gold hits at Lucky Shot
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
